Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

201822 citationsJournal Article

Authors

Taeang Arai · Chiba Hokusou Hospital

Masanori Atsukawa · Chiba Hokusou Hospital

Akihito Tsubota · Jikei University School of Medicine

Tadashi Ikegami · Tokyo Medical University Ibaraki Medical Center

Noritomo Shimada · Otemae Hospital

Keizo Kato · Shinmatsudo Central General Hospital

Hiroshi Abe

Abstract

The present study showed that the effects and safety of OBV/PTV/r therapy in genotype 1b chronic hepatitis C patients with non-dialysis CKD were not inferior to those in patients without CKD.

Topics & Keywords

Hepatitis C virus research HIV/AIDS drug development and treatment Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology Research

Volume 48, Issue 7, pp. 549-555

DOI: 10.1111/hepr.13058

Field-Weighted Citation Impact: 2.62